A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study

被引：0

作者：

Daniele, Bruno

Di Maio, Massimo

Gallo, Ciro

Gasbarrini, Antonio

Carteni, Giacomo

Di Costanzo, Giovan Giuseppe

Craxi, Antonio

Cabibbo, Giuseppe

Bolondi, Luigi

Granito, Alessandro

Missale, Gabriele

Frassoldati, Antonio

Angelico, Mario

Roselli, Mario

Daniele, Gennaro

Perrone, Francesco

机构：

[1] G Rummo Hosp, Benevento, Italy

[2] Natl Canc Inst, Clin Trials Unit, Naples, Italy

[3] Univ Naples 2, Naples, Italy

[4] Policlin Univ Agostino Gemelli, Rome, Italy

[5] Azienda Osped Rilievo Nazl A Cardarelli, Naples, Italy

[6] Azienda Osped Univ, Policlin Paolo Giaccone, Palermo, Italy

[7] Azienda Osped Univ Policlin St Orsola Malpighi, Bologna, Italy

[8] Azienda Osped Univ Parma, Parma, Italy

[9] Az Osped Univ Arcispedale St Anna Ferrara, Ferrara, Italy

[10] Azienda Osped Univ Policlin Tor Vergata, Rome, Italy

[11] Natl Canc Inst, Naples, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4151

引用

页数：1

共 50 条

[21] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
Abou-Alfa, Ghassan K.
Niedzwieski, Donna
Knox, Jennifer J.
Kaubisch, Andreas
Posey, James
Tan, Benjamin R.
Kavan, Petr
Goel, Rakesh
Lammers, Philip Edward
Bekaii-Saab, Tanios S.
Tam, Vincent Channing
Rajdev, Lakshmi
Kelley, Robin Kate
Siegel, Abby B.
Balletti, Jennifer
Harding, James J.
Howard, Lawrence Schwartz
Goldberg, Richard M.
Bertagnolli, Monica M.
Venook, Alan P.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
Abou-Alfa, Ghassan K.
Niedzwieski, Donna
Knox, Jennifer J.
Kaubisch, Andreas
Posey, James
Tan, Benjamin R.
Kavan, Petr
Goel, Rakesh
Murray, John J.
Bekaii-Saab, Tanios S.
Tam, Vincent Channing
Rajdev, Lakshmi
Kelley, Robin Kate
Siegel, Abby
Balletti, Jennifer
Harding, James J.
Schwartz, Lawrence Howard
Goldberg, Richard M.
Bertagnolli, Monica M.
Venook, Alan P.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[23] Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
Belani, C. P.
Brodowicz, T.
Ciuleanu, T.
Kim, J. H.
Krzakowski, M.
Laack, E.
Wu, Y. L.
Peterson, P.
Krejcy, K.
Zielinski, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[24] Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
Belani, C. P.
Brodowicz, T.
Ciuleanu, T.
Kim, J. H.
Krzakowski, M.
Laack, E.
Wu, Y. L.
Peterson, P.
Krejcy, K.
Zielinski, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik-Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han Chong
Gorbunova, Vera
Eskens, Ferry
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El Nowiem, Saied
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[26] Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care
Stefanini, B.
Bucci, L.
Santi, V.
Reggidori, N.
Lani, L.
Granito, A.
Pellizzaro, F.
Cabibbo, G.
Di Marco, M.
Ghittoni, G.
Campani, C.
Svegliati-Baroni, G.
Foschi, F. G.
Giannini, E. G.
Biasini, E.
Saitta, C.
Magalotti, D.
Sangiovanni, A.
Morisco, F.
Gasbarrini, A.
Rapaccini, G. L.
Masotto, A.
Sacco, R.
Vidili, G.
Mega, A.
Azzaroli, F.
Nardone, G.
Brandi, G.
Sabbioni, S.
Brunetto, M. R.
Vitale, A.
Trevisani, F.
DIGESTIVE AND LIVER DISEASE, 2023, 55 : S222 - S223
[27] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G. K.
Qin, S.
Ryoo, B-Y.
Lu, S-N.
Yen, C-J.
Feng, Y-H.
Lim, H. Y.
Izzo, F.
Colombo, M.
Sarker, D.
Bolondi, L.
Vaccaro, G.
Harris, W. P.
Chen, Z.
Hubner, R. A.
Meyer, T.
Sun, W.
Harding, J. J.
Hollywood, E. M.
Ma, J.
Wan, P. J.
Ly, M.
Bomalaski, J.
Johnston, A.
Lin, C-C.
Chao, Y.
Chen, L-T.
ANNALS OF ONCOLOGY, 2018, 29 (06) : 1402 - 1408
[28] Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
Finn, Richard S.
Chan, Stephen L.
Zhu, Andrew X.
Knox, Jennifer J.
Cheng, Ann-Lii
Siegel, Abby B.
Bautista, Oliver
Kudo, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
Finn, R. S.
Chan, S. L.
Zhu, A. X.
Knox, J.
Cheng, A-L.
Siegel, A. B.
Bautista, O.
Kudo, M.
ANNALS OF ONCOLOGY, 2017, 28
[30] Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
Van Cutsem, E.
Yoshino, T.
Lenz, H-J.
Lonardi, S.
Falcone, A.
Limon, M. L.
Saunders, M. P.
Sobrero, A.
Maiello, E.
Park, Y. S.
Ferreiro Monteagudo, R.
Hong, Y. S.
Tomasek, J.
Taniguchi, H.
Ciardiello, F.
Hocke, J.
Oum'hamed, Z.
Vlassak, S.
Studeny, M.
Tabernero, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →